Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial.

  title={Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial.},
  author={Aimee L. McRae‐Clark and Nathaniel L. Baker and Kevin M. Gray and Therese K. Killeen and Amanda Wagner and Kathleen T. Brady and C. Lindsay DeVane and Jessica Norton},
  journal={Drug and alcohol dependence},

Figures and Tables from this paper

Vilazodone for cannabis dependence: A randomized, controlled pilot trial.

Vilazodone was not more efficacious than placebo in reducing cannabis use, with women having worse cannabis use outcomes than men and gender should be considered as an important variable in future trials.

Depressive symptoms and cannabis use in a placebo-controlled trial of N-Acetylcysteine for adult cannabis use disorder

Depression may be a risk factor for poor CUD treatment outcome and therefore should be addressed in the context of treatment, but results do not support the use of NAC to concurrently treat co-occurring depressive symptoms and CUD in adults.

Pharmacotherapies for cannabis dependence.

There was no difference in the likelihood of withdrawal from treatment due to adverse effects with THC preparations, SSRIs antidepressants, mixed action antidepressants, anticonvulsants and mood stabilisers, buspirone and N-acetylcysteine compared to placebo (low- to very low-quality evidence), and abstinence at end of treatment was no more likely than with placebo.

Pharmacotherapies for cannabis dependence.

There was some evidence that treatment with preparations containing THC was associated with reduced cannabis withdrawal symptoms and craving, but this latter outcome could not be quantified and the utility of most of the medications to promote cannabis abstinence at the end of treatment was insufficient.

Non-abstinent treatment outcomes for cannabis use disorder.

Quetiapine treatment for cannabis use disorder.

Evidence-based Treatment Options in Cannabis Dependency.

Cognitive behavior therapy (CBT) combined with other techniques has been found to have a moderate to large effect on the amount of cannabis consumed as well as on the level of psychosocial functioning or the dependence syndrome.

Buspirone: Back to the Future.

  • R. Howland
  • Psychology, Medicine
    Journal of psychosocial nursing and mental health services
  • 2015
Buspirone may be considered a treatment option for managing irritability, agitation, and aggression in older adult patients with dementia as well as in pediatric patients, although additional effectiveness studies are warranted.



A placebo-controlled trial of buspirone for the treatment of marijuana dependence.

A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents.

This is the first randomized controlled trial of pharmacotherapy for cannabis dependence in any age group to yield a positive primary cessation outcome in an intent-to-treat analysis, and findings support NAC as a pharmacotherapy to complement psychosocial treatment for Cannabis dependence in adolescents.

A Proof-of-Concept Randomized Controlled Study of Gabapentin: Effects on Cannabis Use, Withdrawal and Executive Function Deficits in Cannabis-Dependent Adults

This phase IIa proof-of-concept pilot study provides preliminary support for the safety and efficacy of gabapentin for treatment of cannabis dependence, and provides an alternative conceptual framework for Treatment of addiction aimed at restoring homeostasis in brain stress systems that are dysregulated in drug dependence and withdrawal.

A preliminary trial: double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence.

Results indicated an increased probability of achieving abstinence over the course of treatment and a decrease in the severity of cannabis dependence and the withdrawal symptom of irritability.

Multisite, randomized, double-blind, placebo-controlled pilot clinical trial to evaluate the efficacy of buspirone as a relapse-prevention treatment for cocaine dependence.

The results suggest that busPirone is unlikely to have a beneficial effect on preventing relapse to cocaine use and that buspirone for cocaine-dependent women may worsen their cocaine use outcomes.

Treatment of cannabis dependence using escitalopram in combination with cognitive-behavior therapy: a double-blind placebo-controlled study

It is premature to conclude that selective serotonin reuptake inhibitors are not effective for treatment of the cannabis withdrawal syndrome, but a high dropout rate and effects of low abstinence rates on measures of anxiety, depression and withdrawal are premature.

Treatment of cannabis use disorders: a review of the literature.

It is concluded that while a number of psychotherapies have been found to be effective in treating this disorder, with the exception of adding vouchers to reinforce negative urine toxicology screens, no form of psychotherapy has been foundTo be more effective than any other.

Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population.

It is suggested that combining CM with buPropion for the treatment of cocaine addiction may significantly improve outcomes relative to bupropion alone.